BofA cuts Novo Nordisk shares target on expected Q1 earnings miss

Published 28/03/2025, 14:28
© Reuters

Investing.com -- Bank of America (BofA) on Friday lowered its price target for Novo Nordisk (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its megahit drugs Wegovy and Ozempic, lag.

BofA analysts expect Novo Nordisk’s first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year increase, and earnings before interest and taxes (EBIT) to hit DKK 36 billion, up 14% from the previous year. These figures are approximately 1-2% below the Visible Alpha consensus.

The analysts have identified several key factors that could contribute to a potential earnings miss for the first quarter.

These include a challenging comparison with the first quarter of 2024 due to a large gross-to-net (GTN) benefit that significantly boosted growth, as well as the highest margin quarter of fiscal year 2024, which sets a high comparison baseline.

Moreover, there could be increased sales, general, and administrative (SG&A) expenses related to demand creation and Catalent (NYSE:CTLT) dilution. The BofA team projects a margin decline of around 120 basis points year-over-year.

Specifically, the bank forecasts Ozempic’s first-quarter sales at DKK 31 billion, a 10% year-over-year increase but roughly 6% below consensus. Wegovy’s sales are predicted to be DKK 18.6 billion, with an anticipated sequential decline in the U.S. due to decreasing total prescriptions (TRx) and a slight assumed price decline.

Looking ahead, BofA expects Novo Nordisk to lower its sales guidance from 16-24% in constant exchange rates (CER) to 14-22%, with firm’s own forecasts at the lower end of this new range.

“Within this we assume (1) limited Ozempic/Wegovy inflection in 2Q, given compounders remain until May. 2Q is an “easy” comp for both Ozempic/Wegovy; (2) The key unknown is if a 2H25 inflection happens against tougher 2H24 comps,” BofA analysts led by Sachin Jain noted.

“Our forecasts assume a Wegovy exit rate of 340k and Ozempic TRx increase to 650k, on which we have low visibility,” they added.

BofA has reduced its fiscal year 2025/26 earnings per share (EPS) estimates from high single digits to low double digits percentage.

Consequently, the firm has lowered its price objective for Novo Nordisk to DKK 910/$127.40 from the previous DKK 1,075/$159.4.

Despite the near-term headwinds, BofA maintains a Buy rating on Novo Nordisk’s stock. The firm highlights the drugmaker’s current valuation, which is near a 10-year low on price-to-earnings (PE) ratio, and the stock’s multiples that reflect a ’cliff-stock’ despite robust forward sales compound annual growth rate (CAGR) projections of approximately 12-13%.

“Novo remains a key participant in large obesity/diabetes GLP1 market,” the note concludes.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.